AN2 Therapeutics (ANTX) Net Income towards Common Stockholders (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$10.0 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 5.83% year-over-year to -$10.0 million in Q1 2026; TTM through Mar 2026 was -$34.6 million, a 23.81% increase from a year earlier, with the FY2025 full-year figure at -$35.2 million, up 31.46% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$10.0 million, down from -$8.7 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for ANTX reached as high as -$6.5 million in Q2 2025 and fell as low as -$16.9 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$12.0 million across 5 years, with a median of -$11.3 million in 2022.
• Across the five-year window, Net Income towards Common Stockholders plunged 237.31% in 2022 and jumped 55.49% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$11.8 million in 2022, then plunged by 42.7% to -$16.9 million in 2023, then soared by 55.49% to -$7.5 million in 2024, then slipped by 15.79% to -$8.7 million in 2025, then retreated by 15.13% to -$10.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$10.0 million in Q1 2026, -$8.7 million in Q4 2025, and -$9.4 million in Q3 2025.